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LETTER 
HIV-1-infected (HIV+) children and adolescents are at significant risk of non-
Hodgkin lymphoma (NHL), most typically diffuse large B-cell (DLBC), high-grade 
plasmablastic, or Burkitt variants [1, 2]. The risk of developing lymphoma in 
HIV-infected individuals appears directly related to nadir CD4 count [3-5] and to 
ongoing HIV viraemia. Consistent virological suppression with antiretroviral 
therapy (ART) is, by contrast, highly protective [5, 6].  During the pre- and early-
ART era, profound immunosuppression and detectable viraemia were common 
occurrences in HIV+ children, and antiretroviral options were limited by 
significant toxicities, unpalatable formulations and poor virological durability [7, 
  
8]. Early ART regimens were frequently unlicensed, therefore underpinned by 
low-quality clinical evidence, in paediatric populations. As a result, inadvertent 
under-dosing was observed in up to 62% of children in the United Kingdom (UK) 
and Ireland between 1997 and 2005 [9]. Virological failure and subsequent 
accumulation of resistance-associated mutations are therefore common in this 
population at the point of transition to adult services [10]. Thus, despite the 
advantages of modern ART regimens and multi-disciplinary care in resource-rich 
countries, many adolescents with vertically-acquired HIV will bear the burden of 
chronic, sub-optimal virological control in childhood alongside the significant 
challenges of maintaining consistent treatment concordance (and virological 
suppression) during adolescence [11].  
 
We conducted a retrospective review of all new lymphoma diagnoses in a cohort 
of adolescents transitioning from paediatric to an adult HIV service between 
January 2007 and January 2015. Our service, based at Mortimer Market Centre in 
Central London, provides free HIV-care for around 4500 patients aged over 15 
years from all areas of the UK including a dedicated adolescent clinic to support 
transition between paediatric and adult HIV services.  
 
Over the eight-year period, 147 individuals transitioned their HIV care to our 
service from paediatric services. Among these, we identified five new cases of 
lymphoma. The total observation time was 1176 person-years. Three patients 
were male. The median age at HIV-1 diagnosis was 6 years (range 0-17 years) 
and 19 yrs (range 18-23) at lymphoma diagnosis, respectively. Median (range) 
CD4 counts at lymphoma diagnosis and pre-ART nadir were 340 (180 -550) and 
  
157 (90-220) cells/μL, respectively.  All five patients were known to have a 
history of intermittent or complete non-adherence in the five years prior to 
transitioning care, although three were known to have an undetectable HIV-1 VL 
at lymphoma diagnosis. Full, historical HIV-1 VL data were available for four 
patients (Figure 1). The mean time from initial engagement with HIV services to 
lymphoma diagnosis was 114 months (range 30-199). Mean estimated 
cumulative exposure to detectable HIV-1 viraemia (obtained via historical VL 
data, clinic attendance notes and electronic prescriptions for ART) was 170.5 
months (range 118-234). Dual and triple-class ART resistance was present in 
one and two patients, respectively; all patients had durable therapeutic options 
available to them at lymphoma diagnosis.  
 
Four patients had DLBC, the fifth had marginal zone lymphoma which 
transformed during chemotherapy to a high-grade DLBC. All five patients had 
disseminated disease (Ann Arbor stage III or IV) at initial presentation: B 
symptoms were present in four. Immunohistochemistry showed four were 
positive for Epstein-Barr virus (EBV)-encoded small RNAs (EBERs). Quantitative 
assessment of blood/tumour EBV load is not part of routine clinical assessment 
at diagnosis of HIV-associated lymphoma in UK [12]. Likewise, markers of 
immune activation, such as tumour necrosis factor-α, β-microglobulin, and 
interleukin-10, are not assayed routinely in HIV-infected patients in our 
treatment centre. 
 
The lymphoma incidence-rate (IR) for these five patients over the eight-year 
period is 0.425/100 person-years [95% Confidence Interval (CI) =0.424-0.426]. 
  
This figure is similar to rates previously reported in HIV-infected children and 
infants during the pre-ART era [IR =0.386/100 person-years, 95% CI =0.386-
0.387: IR ratio (IRR) =1.10; 95% CI =0.98-1.24, p  =0.1] [1]. Moreover, the IR of 
NHL seen in this cohort signficantly exceeds the average rate observed between 
2008-2010 among 15-24 year-olds in the UK general population (IR 
=6.4/100,000 person-years, 95% CI =4.93-8.17: IRR =25.9; 95% CI =8.31-61.7, p 
<0.0001) [12].  
 
It is established that the risk of developing HIV-associated lymphoma at any 
given time-point directly relates to the magnitude of immunosuppression. More 
specifically, data from several cohort studies suggest that current (rather than 
nadir) CD4 count and HIV-1 viral load are the most significant parameters in 
determining lymphoma-risk in multivariate analysis [6, 14, 15]. It is also 
suggested that cumulative exposure to detectable HIV-1 viraemia increases 
lymphoma-risk in a dose-dependent fashion [16]. These observations are borne 
out in the wider epidemiology, such that the observed incidence of HIV-
associated NHL has fallen by up to 90% during the ART era [15, 17]. 
Nevertheless, the incidence of NHL observed in our cohort is in stark excess of 
that observed in both the age-matched UK general population and in a cohort of 
HIV-infected adults with undetectable viraemia on ART – a reasonable model, we 
suggest, for the wider UK population in specialist HIV care [18]. Likewise, despite 
the universal availability of effective ART, the observed rate of lymphoma in our 
cohort was comparable to that seen in UK children with AIDS in the pre-ART era.   
All of the lymphoma cases observed in our cohort occurred in adolescents with a 
prolonged history of poor ART concordance and detectable HIV-1 viraemia 
  
during childhood and early adolescence. While the small sample size limits firm 
conclusions, we hypothesise that this represents a perfect scenario for the 
development of lymphoma. Uncontrolled HIV-1 infection engenders a significant 
pro-inflammatory state, with high levels of immune activation occurring 
synchronously with immunosuppression [19, 20]. B-lymphocyte 
hyperstimulation, as indicated by polyclonal hypergammaglobulinaemia, is a key 
feature [21]. This phenomenon is amplified in the HIV-infected child as the 
nascent immune system fails to co-ordinate an efficient response to HIV-1 with 
higher viraemic set points and a faster progression to AIDS compared to those 
infected during later life [22-24]. Therefore, HIV-infected children bear a 
particularly heavy burden of immunosuppression, resulting in impaired 
surveillance and cytotoxic control of malignant cells and oncogenic viruses.  
 
EBV is the most common oncogenic virus involved in the pathogenesis of HIV-
associated lymphoma, with plasma EBV VL correlating directly with risk [25]. 
Higher plasma EBV DNA loads have been observed in children with uncontrolled 
HIV-1 infection compared with age-matched counterparts taking effective ART 
[26, 27].  Moreover, co-infection with EBV types 1 and 2 appears more common 
in children with uncontrolled HIV-1, which may further increase the risk of 
lymphomagenesis [28]. We therefore postulate that the potent theoretical 
interactions between uncontrolled HIV-1 infection, oncogenic viruses and an 
immature immune system serve to greatly increase lymphoma-risk in HIV-
infected adolescents with vertically-acquired infection over that seen in those 
infected via other routes. However, we acknowledge that the lack of 
  
supplementary data concerning quantitative EBV exposure and immune 
activation in our patients may limit firm conclusions in this regard.  
 
With increased survival of children with vertically-acquired HIV infection, the 
numbers of adolescents transitioning from pediatric to adult HIV services in the 
UK has significantly increased in recent years, and although numerically a small 
group, these patients require considerable specialist care. This is important not 
only to support ART concordance at a time of immense psychosocial challenge, 
but also to monitor for nascent complications associated with past or present 
immunosuppression. Our findings suggest that clinicians caring for adolescents 
with vertically-acquired HIV infection should maintain a high level of vigilance 
for symptoms suggestive of lymphoma and should have a low threshold for 
diagnostic evaluation, even in the presence of undetectable viraemia on ART.  
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Figure 1:  HIV-1 viraemia in the time period prior to diagnosis of lymphoma  
Key: Historical viral load data was available for four cases. The remaining patient was known to have an undetectable HIV-1 viral load at 
the time of lymphoma diagnosis. *: Antiretroviral therapy (ART) (re)commenced. **: This individual was diagnosed with HIV-1 
infection, and was commenced on ART immediately. He defaulted from care after 1 month, stopping ART and represented 24 months 
later with lymphoma-related symptoms and an HIV-1 VL of 3.4 log copies/ml.  
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